Clariant compounds its interest in Asia's medical market

Comments Email
Photo by Clariant International Ltd. Clariant International Ltd. will add a second compounding line for the medical industry in Asia.

Continuing its push into growing Asia-Pacific markets, Clariant International Ltd. is adding a compounding line in Singapore for medical grade resins.

The compounding extruder line will be capable of quickly producing batches ranging from 1 to 5 tonnes and more, the company announced at the September Medtec China trade show in Shanghai. Clariant already has one such line in operation at its Singapore facility.

"By the time our newly added compounding line goes on-stream in Singapore, Clariant will be able to supply precolored compound materials that address the particular needs of the healthcare industry in the Asia Pacific region," said Steve Duckworth, head of the global segment medical and pharmaceutical for the Swiss-based chemical giant.

"Medical processors can take advantage of our ready-to-use compounds that bring ease of handling, as well as controlled, consistent and compliant materials," he said.

At last year's Chinaplas trade show in Shanghai, Clariant announced an aggressive plan to target the Asia-Pacific region, including posting Christian Kohlpaintner, a member of the company's four-member executive committee, to Shanghai.

The company is on track to open its Asia-Pacific headquarters and R&D center in Shanghai next year.

Earlier this year, Clariant announced plans to add two new production facilities at its Zhenjiang, China, plant next year, for plastics additives and wax coatings.


Select from the list below to subscribe to customized Plastics News Europe e-mail news alerts. Check the options you wish to receive.